Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 3, 2015, Pages 141-151

  Wojciechowski, Piotr ^a   Niemczyk Szechowska, Patrycja ^a   Olewińska, Elzbieta ^a   Jaros, Patrycja ^a   Mierzejewska, Barbara ^b   Skarzyńska Duk, Joanna ^b   Małecki, Maciej T ^c,d   Ryś, Przemysław ^a  

^a HTA CONSULTING   (Poland)

^b Novo Nordisk Pharma Ltd   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Insulin aspart; Insulin therapy; Rapid acting insulin analog; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; INSULIN TREATMENT; MEAL; MEDLINE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; META ANALYSIS; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84928987337     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2705     Document Type: Article

References (47)

1. American Diabetes Association (ADA). Standards of medical care in diabetes - 2013. Diabetes Care. 2013; 36 Suppl: S11-S66.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
3. Internetional Diabetes Federation. Global Guideline for Type 2 Diabetes. 2012. Available from: http://www.idf.org/sites/default/files/IDF%20T2DM%20Guideline.pdf. Accessed December 2, 2013.
4. IDF/ISPAD. Global IDF/ISPAD guideline for diabetes in childhood and adolescence. 2011. Available from: http://www.idf.org/sites/default/files/Di-abetes-in-Childhood-and-Adolescence-Guidelines.pdf. Accessed December 2, 2013.
5. NICE. Type 2 diabetes: the management of type 2 diabetes [Internet]. 2008. Available from: http://www.nice.org.uk/CG66. Accessed December 2, 2013.
6. Cyganek K, Klupa T, Szopa M, et al. Medical care of pregnant women with type 1 diabetes: current guidelines and clinical practice. Pol Arch Med Wewn. 2013; 123: 59-65.
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329: 977-986.
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 854-865.
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853.
10. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589.
11. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353: 2643-2653.
12. Donner T, Muñoz M. Update on insulin therapy for type 2 diabetes. J Clin Endocrinol Metab. 2012; 97: 1405-1413.
13. Maraka S, Morey-Vargas OL, Montori VM. Should we use intensive hypoglycemic treatment in patients with advanced type 2 diabetes? Pol Arch Med Wewn. 2014; 124: 657-658.
14. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363: 1410-1418.
15. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA. 2003; 289: 2254-2264.
16. Rolla A. Pharmacokinetic and Pharmacodynamic Advantages of Insulin Analogues and Premixed Insulin Analogues Over Human Insulins: Impact on Efficacy and Safety. Am J Med. 2008; 121 (6 Suppl): S9-S19.
17. Ma Z, Parkner T, Frystyk J, et al. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study. Diabetes Technol Ther. 2012; 14: 589-595.
18. Rys P, Pankiewicz O, Łach K, et al. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab. 2011; 37: 190-200.
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
20. Higgins JT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] [Internet]. The Cochrane Collaboration; 2011. www.cochrane-handbook.org. Accessed April 22, 2013.
21. Arslanian S, Foster C, Wright NM, et al. Insulin aspart compared to regular insulin and insulin lispro in basal bolus therapy with NPH to treat pediatric patients with type 1 diabetes mellitus. Diabetiologia. 2005; 48 (Suppl 1): A327.
22. Cherubini V, Iannilli A, Iafusco D, et al. Premeal insulin treatment during basal-bolus regimen in young children with type 1 diabetes. Diabetes Care. 2006; 29: 2311-2312.
23. Danne T, Råstam J, Odendahl R, et al. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabetes. 2007; 8: 278-285.
24. Pańkowska E, Nazim J, Szalecki M, Urban M. Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children. Diabetes Technol Ther. 2010; 12: 413-418.
25. Ampudia-Blasco FJ, Girbes J, Sanz J, et al. Rgular insulin is as effective as rapid-acting insulin analogs in combination with glargine insulin in type 1 diabetic patients. Diabetologia. 2005; 48 (Suppl 1): A92.
26. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002; 25: 439-444.
27. DeVries JH, Lindholm A, Jacobsen JL, et al. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med J Br Diabet Assoc. 2003; 20: 312-318.
28. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med J Br Diabet Assoc. 2004; 21: 769-775.
29. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med J Br Diabet Assoc. 2000; 17: 762-770.
30. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000; 23: 583-588.
31. Tamás G, Marre M, Astorga R, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract. 2001; 54: 105-114.
32. Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004; 27: 1023-1027.
33. Herrmann BL, Kasser C, Keuthage W, et al. Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2013; 121: 210-213.
34. Maiti R, Jaida J, Leander PJI, et al. Cardioprotective role of insulin: Advantage analogues. J Res Med Sci. 2012; 17: 642-648.
35. Pala L, Mannucci E, Dicembrini I, Rotella CM. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract. 2007; 78: 132-135.
36. Raskin P, McGill J, Kilo C, Boss A. Human Insulin Analog (Insulin Aspart, IAsp) is Comparable to Human Insulin (HI) in Type 2 Diabetes. Diabetes. 1999; 48 (Suppl 1): A355.
37. Banerjee S, Tran K, Li H, et al. Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness. Ott Can Agency Drugs Technol Health. 2007.
38. Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009; 180: 385-397.
39. Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2010; 16: 486-505.
40. Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013; 5: 482-491.
41. Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2012; 14: 433-446.
42. Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011; 34: 2508-2514.
43. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2003; 9: 530-543.
44. Yale JF. Nocturnal hypoglycemia in patients with insulin-treated diabetes. Diabetes Res Clin Pract. 2004; 65 (Suppl 1): S41-S46.
45. The diabetes control and complications trial research Group Epidemiology of severe hypoglycemia in the Diabetes Control and complications trial. Am J Med. 1991; 90: 450-459.
46. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011; 14: 646-655.
47. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ. 2012; 15: 77-86.